Apto Global

Aptose Biosciences is a clinical-stage biotechnology company focused on developing personalized small molecule therapies for the treatment of hematologic malignancies. The company's lead clinical candidate is tuspetinib, a once-daily oral myeloid kinase inhibitor targeting key drivers of acute myeloid leukemia (AML), including FLT3, SYK, and JAK kinases. Aptose is also advancing luxeptinib, a potent dual inhibitor of SYK and FLT3, which is being evaluated in Phase 1/2 trials for patients with AML and certain B-cell malignancies. By leveraging its expertise in kinase inhibition and precision medicine, Aptose aims to provide novel treatment options for patients who have failed current standard-of-care therapies. The company maintains operations in both Toronto, Canada, and San Diego, California.